Weiss Ratings Reaffirms “Sell (D-)” Rating for 4D Molecular Therapeutics (NASDAQ:FDMT)

Weiss Ratings reaffirmed their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT) in a report published on Saturday morning,Weiss Ratings reports.

A number of other brokerages have also issued reports on FDMT. Chardan Capital reissued a “buy” rating and issued a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday, November 14th. Leerink Partners cut their target price on 4D Molecular Therapeutics from $31.00 to $27.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. BMO Capital Markets lowered 4D Molecular Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price target for the company from $40.00 to $15.00 in a research report on Monday, January 13th. Morgan Stanley dropped their price objective on 4D Molecular Therapeutics from $8.00 to $6.00 and set an “underweight” rating for the company in a report on Monday, January 13th. Finally, HC Wainwright reissued a “buy” rating and set a $36.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, January 13th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. According to data from MarketBeat.com, 4D Molecular Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $38.56.

4D Molecular Therapeutics Trading Down 2.1 %

Shares of NASDAQ:FDMT traded down $0.10 during trading on Friday, reaching $4.58. 927,608 shares of the company traded hands, compared to its average volume of 992,118. 4D Molecular Therapeutics has a 52-week low of $4.50 and a 52-week high of $36.25. The business’s fifty day moving average is $6.66 and its 200-day moving average is $11.49. The firm has a market capitalization of $211.73 million, a price-to-earnings ratio of -1.61 and a beta of 2.81.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. nVerses Capital LLC purchased a new stake in 4D Molecular Therapeutics in the third quarter worth about $40,000. Values First Advisors Inc. bought a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $57,000. China Universal Asset Management Co. Ltd. boosted its position in shares of 4D Molecular Therapeutics by 64.6% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,995 shares of the company’s stock worth $108,000 after purchasing an additional 3,922 shares in the last quarter. Proficio Capital Partners LLC purchased a new stake in shares of 4D Molecular Therapeutics in the 3rd quarter worth approximately $108,000. Finally, Marquette Asset Management LLC bought a new position in 4D Molecular Therapeutics during the 4th quarter valued at approximately $116,000. 99.27% of the stock is currently owned by institutional investors.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.